News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZS Pharma To Present Results Of Phase 2 Trial Of ZS-9 At 2014 American College of Cardiology’s Annual Scientific Session


3/27/2014 9:44:23 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that results from its Phase 2 trial of ZS-9, a novel investigational treatment for hyperkalemia, will be presented in a poster session at the American College of Cardiology (ACC) 63rd Annual Scientific Session & Expo in Washington, D.C. The Phase 2 proof-of-concept study assessed the safety and efficacy of ZS-9 in treating chronic kidney disease (CKD) patients with hyperkalemia, a life-threatening condition that is characterized by higher than normal levels of potassium (K+) in the blood serum.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES